Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III , Active‐Controlled Study
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71069 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Unnikrishnan Ambika Gopalakrishnan und 26 weiteren Autor:innen. Beteiligte Einrichtung: Chellaram Diabetes Institute, Pune, Maharashtra, India. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Overweight, Anti-Obesity Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sun Pharmaceutical Industries Limited, Sun Pharma.
Abstract (Originalsprache)
Aim
To evaluate and compare the efficacy, safety, and immunogenicity of a synthetic semaglutide injection (Test semaglutide) with Wegovy (Reference semaglutide) injection for weight management. Materials and Methods This randomized, Phase III, non‐inferiority study included adults with obesity or overweight with or without comorbidities from 21 centers in India. A total of 270 patients with body mass index ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with the presence of at least one of the weight‐related comorbidities (hypertension, dyslipidemia or type 2 diabetes mellitus) were randomized (2:1) to receive either Test semaglutide ( N = 177) or Reference semaglutide injection ( N = 90) once weekly with dose escalation from 0.25 to 2.4 mg. The primary endpoint was percentage change in bodyweight from baseline to Week 24.
Results
Out of 267 randomized patients, 246 completed the study. At Week 24, mean percent weight change from baseline was −13.8% ± 4.28% in Test and −14.1% ± 4.11% in Reference groups with least‐squares mean difference of 0.26% (95% CI: −0.86% to 1.39%), meeting the criterion for non‐inferiority. The proportion of patients with ≥ 5% and ≥ 10% weight loss were 96.40% and 80.60% in Test, and 98.80% and 80.00% in Reference groups, respectively at Week 24. Improvements in body mass index, waist circumference, SF‐36 total score, and glycemic parameters were comparable between groups. Treatment‐emergent adverse events were reported in 72.30% and 76.70% in the Test and Reference groups, respectively, with gastrointestinal events being the most common.
Conclusions
Test synthetic semaglutide was found to be non‐inferior to Reference semaglutide in weight management with or without comorbidities. Trial Registration Prospectively registered on the Clinical Trials Registry—India, CTRI/2025/04/085487 [Registered on: 24/04/2025], https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTIwNjMx&Enc=&userName=
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chellaram Diabetes Institute, Pune, Maharashtra, India.
- Bhaktivedanta Hospital and Research Institute, Thane, Maharashtra, India.
- Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India.
- G.S.V.M Medical College, Kanpur, Uttar Pradesh, India.
- Jawahar Lal Nehru Medical College, Ajmer, Rajasthan, India.
- King George Hospital, Visakhapatnam, Andhra Pradesh, India.
ORCID-Profile: Shweta Bhandari, Supriya Sonowal, Dipak Patil
Förderung
- Sun Pharmaceutical Industries Limited
- Sun Pharma
Zitieren
APA
Ambika Gopalakrishnan, U., Joshi, A., Kumar, H., Giri, R., Maheshwari, S., Prasad, V. S., Shukla, J., M Chowdaiah, R., Agrawal, N. K., Rasal, Y., Sahoo, B., Bhandari, S., Gowda, A., Phadke, U., Supe, P., Pathak, N., Chandrappa, A., Sonawane, A., Bahulikar, Y., …, & Mehta, S. (2026). Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III , Active‐Controlled Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71069
Vancouver
Ambika Gopalakrishnan U, Joshi A, Kumar H, Giri R, Maheshwari S, Prasad VS, et al. Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III , Active‐Controlled Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71069
BibTeX
@article{AmbikaGopalakrishnan2026,
author = {Ambika Gopalakrishnan, Unnikrishnan and Joshi, Ameya and Kumar, Harish and Giri, Richa and Maheshwari, Sanjiv and Prasad, Valluri Satya and Shukla, Jitendra and M Chowdaiah, Rekha and Agrawal, Nutan Kumar and Rasal, Yogesh and Sahoo, Banshidhar and Bhandari, Shweta and Gowda, Ambanna and Phadke, Uday and Supe, Pravin and Pathak, Niranjan and Chandrappa, Ambrish and Sonawane, Ashutosh and Bahulikar, Yash and Bhaskar, Amit and Radhakrishnan, Arunkumar and Yadav, Priyanka and Pandit, Sucheta and Sonowal, Supriya and Patil, Dipak and Ghadge, Pravin and Mehta, Suyog},
title = {Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III , Active‐Controlled Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71069}
}
EUVIMED